ReviewJournal of the American Society of Nephrology : JASN2017
Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.
Review in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials.Renal failure · 2022Pooled it
- Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.Medicine · 2020Trial
- Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.Pediatric nephrology (Berlin, Germany) · 2018Trial
- Add-On Effect of Angiotensin Receptor Blockade (Candesartan) on Clinical Remission in Active IgA Nephropathy Patients Treated with Steroid Pulse Therapy and Tonsillectomy: a Randomized, Parallel-Group Comparison Trial.Kidney & blood pressure research · 2018Trial
- Early post-treatment remission of proteinuria is associated with long-term prognosis in patients with immunoglobulin A nephropathy.International urology and nephrology · 2025Article
- Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.Frontiers in immunology · 2025Review
- Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?Diagnostics (Basel, Switzerland) · 2024Review
- Cyclic neutropenia and concomitant IgA nephropathy: a case report.BMC nephrology · 2023Article
- Crohn's disease may promote inflammation in IgA nephropathy: a case-control study of patients undergoing kidney biopsy.Virchows Archiv : an international journal of pathology · 2022Article
- Nephropathic Cystinosis: Pathogenic Roles of Inflammation and Potential for New Therapies.Cells · 2022Review
- Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy.Frontiers in immunology · 2022Article
- Evaluation of the Relationships between Intestinal Regional Lymph Nodes and Immune Responses in Viral Infections in Children.International journal of molecular sciences · 2021Article
- Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND).CEN case reports · 2021Article
- Mesangial IgM deposition predicts renal outcome in patients with IgA nephropathy: a multicenter, observational study.Clinical and experimental medicine · 2021Observational
- The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.Renal failure · 2021Article
- Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients.Journal of molecular cell biology · 2021Article
- Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.International urology and nephrology · 2021Article
- Remission of Proteinuria May Protect against Progression to Chronic Kidney Disease in Pediatric-Onset IgA Nephropathy.Journal of clinical medicine · 2020Article
- Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy.EBioMedicine · 2020Article
- Integrated Fecal Microbiome and Serum Metabolomics Analysis Reveals Abnormal Changes in Rats with Immunoglobulin A Nephropathy and the Intervention Effect of Zhen Wu Tang.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is a common chronic glomerular disease that, in most patients, slowly progresses to ESRD. The immune and autoimmune responses that characterize IgAN indicate a potential benefit for corticosteroids. The 2012 Kidney Disease Improving Global Outcome (KDIGO) guidelines suggest giving corticosteroids to patients with rather preserved renal function (GFR>50 ml/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.